Phase II/III Biomarker-Driven Master Protocol For Second Line Therapy Of Squamous Cell Lung Cancer (Screening Step).
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it i
Criteria:
To Be Eligible For This Study, Patients Must Have Squamous Cell Lung Cancer.
Keywords:
Cancer, Lung Cancer, S1400, Squamous Cell
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com